Javascript must be enabled to continue!
Utility of gut-brain electrophysiological coupling in predicting L-Dopa induced dyskinesia in Parkinson’s Disease
View through CrossRef
Abstract
In this study, we focus on Levodopa induced dyskinesia (LID) condition in Parkinson’s Disease (PD) and investigate the mechanistic role of gut-brain coupling in explaining the dyskinesia severity. Earlier studies have provided evidences for abnormal dynamics in the cortico-basal ganglia loops and also in the gut functioning, for explaining LID. However to our knowledge, assessing gut-brain coupling isn’t a standard practice for development of the treatment strategy in LID patients for understanding the odds of dyskinesia onset and progression. In this study, we use scalable data acquisition technologies such as electroencephalography (EEG) and electrogastrography (EGG) for investigating the gut-brain coupling, and for the first time assess its utility to inform about dyskinesia severity in PD patients. We collected data from N=67 subjects (healthy = 26) in middle to old age adulthood and acquire their gut-brain coupling data during various cognitive engagement tasks, using simultaneous EEG and EGG recording setup. Some of our results include that gut-brain coupling can predict the severity of dyskinesia in PD during interoception, especially in hyperventilating and eyes closed resting state paradigms. Second, specific frequencies of gut coupling activity are more sensitive to explaining motor complications. Third, the gut activity differentially couples with different brain regions to explain the symptom severity. The most salient features of our model were the normogastric gut coupling with the temporo-occipital brain region, normogastric gut coupling with the frontal region, and the tachygastric gut coupling with the centro-parietal region. Furthermore of translational significance, the latter two features also significantly interacted with cardiac measures, and the model was able to predict sensitive heart rate variability levels for reducing the symptom severity. Altogether, our study paves way for utitlizing gut-brain coupling as a clinical measure for strategizing interventions in PD.
Title: Utility of gut-brain electrophysiological coupling in predicting L-Dopa induced dyskinesia in Parkinson’s Disease
Description:
Abstract
In this study, we focus on Levodopa induced dyskinesia (LID) condition in Parkinson’s Disease (PD) and investigate the mechanistic role of gut-brain coupling in explaining the dyskinesia severity.
Earlier studies have provided evidences for abnormal dynamics in the cortico-basal ganglia loops and also in the gut functioning, for explaining LID.
However to our knowledge, assessing gut-brain coupling isn’t a standard practice for development of the treatment strategy in LID patients for understanding the odds of dyskinesia onset and progression.
In this study, we use scalable data acquisition technologies such as electroencephalography (EEG) and electrogastrography (EGG) for investigating the gut-brain coupling, and for the first time assess its utility to inform about dyskinesia severity in PD patients.
We collected data from N=67 subjects (healthy = 26) in middle to old age adulthood and acquire their gut-brain coupling data during various cognitive engagement tasks, using simultaneous EEG and EGG recording setup.
Some of our results include that gut-brain coupling can predict the severity of dyskinesia in PD during interoception, especially in hyperventilating and eyes closed resting state paradigms.
Second, specific frequencies of gut coupling activity are more sensitive to explaining motor complications.
Third, the gut activity differentially couples with different brain regions to explain the symptom severity.
The most salient features of our model were the normogastric gut coupling with the temporo-occipital brain region, normogastric gut coupling with the frontal region, and the tachygastric gut coupling with the centro-parietal region.
Furthermore of translational significance, the latter two features also significantly interacted with cardiac measures, and the model was able to predict sensitive heart rate variability levels for reducing the symptom severity.
Altogether, our study paves way for utitlizing gut-brain coupling as a clinical measure for strategizing interventions in PD.
Related Results
d‐DOPA IS UNIDIRECTIONALLY CONVERTED TOl‐DOPA BYd‐AMINO ACID OXIDASE, FOLLOWED BY DOPA TRANSAMINASE
d‐DOPA IS UNIDIRECTIONALLY CONVERTED TOl‐DOPA BYd‐AMINO ACID OXIDASE, FOLLOWED BY DOPA TRANSAMINASE
SUMMARYMany studies have shown that administration ofd‐3, 4‐dihydroxyphenylalanine (d‐dopa) produces contralateral rotation in hemi‐parkinsonian animals comparable tol‐dopa, with l...
Brain Organoids, the Path Forward?
Brain Organoids, the Path Forward?
Photo by Maxim Berg on Unsplash
INTRODUCTION
The brain is one of the most foundational parts of being human, and we are still learning about what makes humans unique. Advancements ...
Effect of the Dopa Decarboxylase Inhibitor MK-486 on L-dopa-Induced Inhibition of Prolactin Secretion: Evidence for CNS Participation in the L-dopa Effects
Effect of the Dopa Decarboxylase Inhibitor MK-486 on L-dopa-Induced Inhibition of Prolactin Secretion: Evidence for CNS Participation in the L-dopa Effects
The present studies were performed in order to determine whether the inhibition of prolactin (Prl) secretion which follows the systemic administration of L-dopa and its conversion ...
L-Dopa Treatment in Parkinson’s Disease
L-Dopa Treatment in Parkinson’s Disease
Double-blind and non-blind therapeutic trials of orally administered L-Dopa in the long-term treatment of Parkinsonism were carried out with 126 patients. For correlative studies t...
The Design and Evaluation of an l-Dopa–Lazabemide Prodrug for the Treatment of Parkinson’s Disease
The Design and Evaluation of an l-Dopa–Lazabemide Prodrug for the Treatment of Parkinson’s Disease
l-Dopa, the metabolic precursor of dopamine, is the treatment of choice for the symptomatic relief of the advanced stages of Parkinson’s disease. The oral bioavailability of l-dopa...
Development of Jelly Loaded with Nanogel Containing Natural L-Dopa from Mucuna pruriens Seed Extract for Neuroprotection in Parkinson’s Disease
Development of Jelly Loaded with Nanogel Containing Natural L-Dopa from Mucuna pruriens Seed Extract for Neuroprotection in Parkinson’s Disease
The first line therapy of patients with Parkinson’s disease, a neurodegenerative disorder caused by the degeneration of dopaminergic neurons, is levodopa (L-dopa) given orally. Rec...
Spectral Signatures of L-DOPA-Induced Dyskinesia Depend on L-DOPA Dose and are Suppressed by Ketamine
Spectral Signatures of L-DOPA-Induced Dyskinesia Depend on L-DOPA Dose and are Suppressed by Ketamine
Abstract
L-DOPA-induced dyskinesias (LID) are debilitating motor symptoms of dopamine-replacement therapy for Parkinson’s disease (PD) that emerg...
[RETRACTED] Gro-X Brain Reviews - Is Gro-X Brain A Scam? v1
[RETRACTED] Gro-X Brain Reviews - Is Gro-X Brain A Scam? v1
[RETRACTED]➢Item Name - Gro-X Brain➢ Creation - Natural Organic Compound➢ Incidental Effects - NA➢ Accessibility - Online➢ Rating - ⭐⭐⭐⭐⭐➢ Click Here To Visit - Official Website - ...

